<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40878848</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2515440</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2025.15440</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Screening for atrial fibrillation (AF) might reduce stroke if it increases long-term AF detection and anticoagulation use compared with usual care.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate the long-term efficacy of AF screening in older individuals at moderate to high risk of stroke using 14-day, patch-based continuous ambulatory electrocardiogram (ECG) monitoring.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">A parallel-group, unblinded, remote randomized clinical trial recruiting from 27 UK primary care practices from May 2, 2019, to February 28, 2022. All eligible individuals 65 years or older with a CHA2DS2VASc score of 3 or higher (men) or 4 or higher (women) with no previous AF or atrial flutter were identified via automated electronic health record searches. Last follow-up was on August 29, 2024, and statistical analysis was conducted from May to July 2025.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Participants were randomized to receive and return an ECG patch monitor by postal mail (intervention, n&#x2009;=&#x2009;2520) or usual care (control, n&#x2009;=&#x2009;2520).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Intention-to-treat analysis of the proportion of participants with AF recorded in primary care records within 2.5 years postrandomization. Exploratory outcomes included exposure to oral anticoagulation and stroke.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 22&#x202f;044 individuals invited, 5040 (22.9%) were randomized. The participants' mean (SD) age was 78 (6) years, 47% were female, and the median (IQR) CHA2DS2VASc score was 4 (3-5). A total of 2126 participants (84.4%) wore and returned the patch. AF was detected by patch in 89 participants (4.2%), 55% of whom had an AF burden less than 10%. After 2.5 years, a postrandomization record of AF was present in 172 individuals (6.8%) in the intervention group vs 136 (5.4%) in the control group (ratio of proportions, 1.26 [95% CI, 1.02-1.57]; P&#x2009;=&#x2009;.03), with consistent results in prespecified subgroups. Mean exposure to oral anticoagulation by 2.5 years was 1.63 months (95% CI, 1.50-1.76) in the intervention group and 1.14 months (95% CI, 1.01-1.26) in the control group (difference, 0.50 months [95% CI, 0.24-0.75]; P&#x2009;&lt;&#x2009;.001). Stroke occurred in 69 participants (2.7%) in the intervention group and 64 (2.5%) in the control group (rate ratio, 1.08 [95% CI, 0.76-1.53]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this remote randomized clinical trial, mail-based AF screening with an ECG patch in older patients at moderate to high risk of stroke led to a modest long-term increase in AF diagnosis at 2.5 years.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ISRCTN Identifier: 15544176.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wijesurendra</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pessoa-Amorim</LastName><ForeName>Guilherme</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Georgina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harper</LastName><ForeName>Charlie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulbulia</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Offer</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Nicholas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A'Court</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurien</LastName><ForeName>Rijo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casadei</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamahealthforum.2022.2419</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2021.23732</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2018.8102</RefSource></CommentsCorrections></CommentsCorrectionsList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Harper reported receiving grants from Novo Nordisk outside the submitted work. Dr Bulbulia reported receiving grants from the British Heart Foundation (BHF) outside the submitted work. Dr Jones reported receiving grants from Wellcome Trust and National Institute for Health and Care Research (NIHR) Academic Clinical Fellowship outside the submitted work. Dr Casadei reported serving as a board member of the Novo Nordisk Foundation outside the submitted work. Dr Bowman reported receiving grants from Novartis, Novo Nordisk, and BHF outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40878848</ArticleId><ArticleId IdType="pmc">PMC12397955</ArticleId><ArticleId IdType="doi">10.1001/jama.2025.15440</ArticleId><ArticleId IdType="pii">2838482</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019;105(24):1860-1867. doi: 10.1136/heartjnl-2018-314267</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2018-314267</ArticleId><ArticleId IdType="pubmed">31444267</ArticleId></ArticleIdList></Reference><Reference><Citation>Friberg L, Rosenqvist M, Lindgren A, Ter&#xe9;nt A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45(9):2599-2605. doi: 10.1161/STROKEAHA.114.006070</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.114.006070</ArticleId><ArticleId IdType="pubmed">25034713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis. J Am Heart Assoc. 2016;5(5):e003206. doi: 10.1161/JAHA.116.003206</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.116.003206</ArticleId><ArticleId IdType="pmc">PMC4889191</ArticleId><ArticleId IdType="pubmed">27207998</ArticleId></ArticleIdList></Reference><Reference><Citation>Thind M, Holmes DN, Badri M, et al. ; ORBIT-AF Investigators and Patients . Embolic and other adverse outcomes in symptomatic versus asymptomatic patients with atrial fibrillation (from the ORBIT-AF Registry). Am J Cardiol. 2018;122(10):1677-1683. doi: 10.1016/j.amjcard.2018.07.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2018.07.045</ArticleId><ArticleId IdType="pubmed">30227964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallenhorst C, Martinez C, Freedman B. Risk of ischemic stroke in asymptomatic atrial fibrillation incidentally detected in primary care compared with other clinical presentations. Thromb Haemost. 2022;122(2):277-285. doi: 10.1055/a-1541-3885</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1541-3885</ArticleId><ArticleId IdType="pubmed">34192776</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001193</ArticleId><ArticleId IdType="pmc">PMC11095842</ArticleId><ArticleId IdType="pubmed">38033089</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Rienstra M, Bunting KV, et al. ; ESC Scientific Document Group . 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae176</ArticleId><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman B, Camm J, Calkins H, et al. ; AF-Screen Collaborators . Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation. 2017;135(19):1851-1867. doi: 10.1161/CIRCULATIONAHA.116.026693</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.026693</ArticleId><ArticleId IdType="pubmed">28483832</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler D, Heidbuchel H, Schnabel RB. Digital, risk-based screening for atrial fibrillation in the European community&#x2014;the AFFECT-EU project funded by the European Union. Eur Heart J. 2021;42(27):2625-2627. doi: 10.1093/eurheartj/ehab050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab050</ArticleId><ArticleId IdType="pubmed">33608697</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson KW, Barry MJ, Mangione CM, et al. ; US Preventive Services Task Force . Screening for atrial fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(4):360-367. doi: 10.1001/jama.2021.23732</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23732</ArticleId><ArticleId IdType="pubmed">35076659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones NR, Taylor CJ, Hobbs FDR, Bowman L, Casadei B. Screening for atrial fibrillation: a call for evidence. Eur Heart J. 2020;41(10):1075-1085. doi: 10.1093/eurheartj/ehz834</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz834</ArticleId><ArticleId IdType="pmc">PMC7060457</ArticleId><ArticleId IdType="pubmed">31811716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesurendra R, Pessoa-Amorim G, Buck G, et al. Active Monitoring for AtriaL FIbrillation (AMALFI): rationale, protocol, and pilot for a pragmatic, randomized, controlled trial of remote screening for asymptomatic atrial fibrillation. Am Heart J. 2025;290:310-324. doi: 10.1016/j.ahj.2025.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2025.07.004</ArticleId><ArticleId IdType="pubmed">40680808</ArticleId></ArticleIdList></Reference><Reference><Citation>Norby FL, Benjamin EJ, Alonso A, Chugh SS. Racial and ethnic considerations in patients with atrial fibrillation: JACC Focus Seminar 5/9. J Am Coll Cardiol. 2021;78(25):2563-2572. doi: 10.1016/j.jacc.2021.04.110</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.04.110</ArticleId><ArticleId IdType="pmc">PMC8688256</ArticleId><ArticleId IdType="pubmed">34887142</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . Atrial fibrillation: diagnosis and management. Updated June 30, 2021. Accessed July 31, 2025. https://www.nice.org.uk/guidance/ng196</Citation></Reference><Reference><Citation>Manly BFJ. Randomization, Bootstrap and Monte Carlo Methods in Biology. 2nd ed. Chapman &amp; Hall; 1997.</Citation></Reference><Reference><Citation>Lubitz SA, Atlas SJ, Ashburner JM, et al. Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF randomized controlled trial. Circulation. 2022;145(13):946-954. doi: 10.1161/CIRCULATIONAHA.121.057014</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.057014</ArticleId><ArticleId IdType="pmc">PMC8960369</ArticleId><ArticleId IdType="pubmed">35232217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaasenbrood F, Hollander M, de Bruijn SHM, et al. Opportunistic screening versus usual care for diagnosing atrial fibrillation in general practice: a cluster randomised controlled trial. Br J Gen Pract. 2020;70(695):e427-e433. doi: 10.3399/bjgp20X708161</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp20X708161</ArticleId><ArticleId IdType="pmc">PMC6988680</ArticleId><ArticleId IdType="pubmed">31988084</ArticleId></ArticleIdList></Reference><Reference><Citation>Uittenbogaart SB, Verbiest-van Gurp N, Lucassen WAM, et al. Opportunistic screening versus usual care for detection of atrial fibrillation in primary care: cluster randomised controlled trial. BMJ. 2020;370:m3208. doi: 10.1136/bmj.m3208</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3208</ArticleId><ArticleId IdType="pmc">PMC7492823</ArticleId><ArticleId IdType="pubmed">32938633</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez MV, Mahaffey KW, Hedlin H, et al. ; Apple Heart Study Investigators . Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909-1917. doi: 10.1056/NEJMoa1901183</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1901183</ArticleId><ArticleId IdType="pmc">PMC8112605</ArticleId><ArticleId IdType="pubmed">31722151</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen JH, Diederichsen SZ, H&#xf8;jberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (the LOOP study): a randomised controlled trial. Lancet. 2021;398(10310):1507-1516. doi: 10.1016/S0140-6736(21)01698-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01698-6</ArticleId><ArticleId IdType="pubmed">34469766</ArticleId></ArticleIdList></Reference><Reference><Citation>Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398(10310):1498-1506. doi: 10.1016/S0140-6736(21)01637-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01637-8</ArticleId><ArticleId IdType="pubmed">34469764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp Gudmundsdottir K, Svennberg E, Friberg L, et al. Randomized invitation to systematic NT-proBNP and ECG screening in 75-year-olds to detect atrial fibrillation: STROKESTOP II. Circulation. 2024;150(23):1837-1846. doi: 10.1161/CIRCULATIONAHA.124.071176</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.071176</ArticleId><ArticleId IdType="pubmed">39217615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes RD, Atlas SJ, Go AS, et al. Effect of screening for undiagnosed atrial fibrillation on stroke prevention. J Am Coll Cardiol. 2024;84(21):2073-2084. doi: 10.1016/j.jacc.2024.08.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.08.019</ArticleId><ArticleId IdType="pubmed">39230544</ArticleId></ArticleIdList></Reference><Reference><Citation>Himmelreich JCL, Veelers L, Lucassen WAM, et al. Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace. 2020;22(5):684-694. doi: 10.1093/europace/euaa005</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euaa005</ArticleId><ArticleId IdType="pmc">PMC7526764</ArticleId><ArticleId IdType="pubmed">32011689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P, Toennis T, Goette A, et al. ; NOAH-AFNET 6 Investigators . Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167-1179. doi: 10.1056/NEJMoa2303062</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2303062</ArticleId><ArticleId IdType="pubmed">37622677</ArticleId></ArticleIdList></Reference><Reference><Citation>Healey JS, Lopes RD, Granger CB, et al. ; ARTESIA Investigators . Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2024;390(2):107-117. doi: 10.1056/NEJMoa2310234</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2310234</ArticleId><ArticleId IdType="pubmed">37952132</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert CM. Oral anticoagulation in device patients with atrial high-rate episodes: shared decision-making after ARTESIA and NOAH-AFNET-6. Circulation. 2024;150(18):1398-1400. doi: 10.1161/CIRCULATIONAHA.124.068018</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.068018</ArticleId><ArticleId IdType="pubmed">39466886</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>